Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Portola Pharmaceuticals Inc.

Latest From Portola Pharmaceuticals Inc.

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.



Pipeline Watch Approvals

Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial

In Bristol/Pfizer's ARISTOPHANES real-world study, the rate of major bleeding with Eliquis was 46% lower than J&J/Bayer's Xarelto and 33% lower than Boehringer's Pradaxa.

Clinical Trials Cardiovascular

Portola May Need Randomized Trial For AndexXa Approval. The Question Is When

Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.

Drug Approval Standards Drug Review

Five Drugs Set For EU Approval, Including Two Orphans

The EU’s CHMP has recommended approval of a number of products including Pfizer’s Mylotarg for acute myeloid leukemia, Ammtek’s Amglidia for neonatal diabetes, and BioCryst Pharmaceuticals/Seqirus’ Alpivab for uncomplicated influenza.

Approvals Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Portola Pharmaceuticals Inc.
  • Senior Management
  • William Lis, CEO
    Mardi C Dier, EVP, CFO
    John T Curnutte, MD, PhD, EVP, R&D
    Tao Fu, EVP, Chief Commercial & Bus. Officer
  • Contact Info
  • Portola Pharmaceuticals Inc.
    Phone: (650) 246-7000
    270 E. Grand Ave.
    So. San Francisco, CA 94080